Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | CD69 | Q07108 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.45 |
| ▸ | FGF1 | P05230 | 1/20 | 0.45 |
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616129 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL13479975 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL29401541 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL31682911 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL5514293 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL7720011 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL6820124 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL5518959 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL3229913 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL10488345 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358950-B2 | IL-17A binding peptides and medical uses thereof | DOMPE' FARMACEUTICI S.P.A. (IT) | 2025-07-15 | — | — | US | claimed |
| EP-4536189-A1 | METHODS FOR TREATING DRY EYE DISEASE | The Schepens Eye Research Institute, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4392780-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | Glycanostics s.r.o. (SK) | 2024-07-03 | — | — | EP | claimed |
| EP-4381291-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2024-06-12 | — | — | EP | claimed |
| WO-2023240155-A1 | METHODS FOR TREATING DRY EYE DISEASE | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023209068-A1 | PERSONALIZED ANTICANCER VACCINE COMPRISING GLYCOENGINEERED TUMOUR CELLS OR TUMOUR CELL FRAGMENTS | CARBOCALYX GMBH (DE) | 2023-11-02 | — | — | WO | claimed |
| WO-2023025927-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-02 | — | — | WO | claimed |
| WO-2023012352-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-02-09 | — | — | WO | claimed |
| US-20220112244-A1 | IL-17A BINDING PEPTIDES AND MEDICAL USES THEREOF | DOMPE' FARMACEUTICI S.P.A. (IT) | 2022-04-14 | — | — | US | claimed |
| US-20260001912-A1 | IL-17A BINDING PEPTIDES AND MEDICAL USES THEREOF | DOMPE FARM SPA (IT) | 2026-01-01 | — | — | US | disclosed |
| US-20250312412-A1 | METHODS FOR TREATING DRY EYE DISEASE | ARAMIS BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12358950-B2 | IL-17A binding peptides and medical uses thereof | DOMPE' FARMACEUTICI S.P.A. (IT) | 2025-07-15 | — | — | US | disclosed |
| EP-4536189-A1 | METHODS FOR TREATING DRY EYE DISEASE | The Schepens Eye Research Institute, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4508429-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023198337-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023041565-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023025927-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023012352-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023006782-A1 | CONJUGATING REAGENTS AND CONJUGATES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-02-02 | — | — | WO | disclosed |
| US-20220112244-A1 | IL-17A BINDING PEPTIDES AND MEDICAL USES THEREOF | DOMPE' FARMACEUTICI S.P.A. (IT) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001912-A1 | IL-17A BINDING PEPTIDES AND MEDICAL USES THEREOF | IL17A, IL36G, IL23R | MAPK1 4262/4885LGALS3 574/4885LGALS8 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.